We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| CSL Limited | ASX:CSL | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.80 | -0.65% | 276.37 | 276.00 | 276.90 | 277.41 | 275.14 | 276.16 | 1,560,327 | 07:50:00 |
From Dec 2019 to Dec 2024
By Chris Wack
Seqirus said Tuesday that the U.S. Food and Drug Administration has approved Afluria Quadrivalent, an influenza vaccine, for use in people six months of age and older.
According to the Summit-N.J.-based Seqirus, the approval also applies to the trivalent formulation of Afluria.
Afluria Quadrivalent was first approved in the U.S. in August 2016 for adults aged 18 years and above, and helps protect against two influenza A strain viruses and two B strain viruses.
Afluria Quadrivalent is available in the U.S. for the 2018-2019 influenza season in prefilled syringes as well as multidose vials.
Seqirus is a unit of Melbourne, Australia-based CSL Limited.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 23, 2018 08:43 ET (12:43 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year CSL Chart |
1 Month CSL Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
